Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on Safety Issues Related to Antihyperglycemic Therapy.

Literature DB >> 26246765

Update on Safety Issues Related to Antihyperglycemic Therapy.

Gandahari Rosa A Carpio, Vivian A Fonseca.

Abstract

The American Diabetes Association emphasizes the importance of individualized patient care in the management of diabetes. One of the important considerations in choosing an antihyperglycemic agent is its side-effect and safety profile. This article reviews the common and clinically significant side effects of each class of agents, including ways to prevent and overcome their occurrence.

Entities: Disease Species

Year: 2014 PMID： 26246765 PMCID： PMC4522884 DOI： 10.2337/diaspect.27.2.92

Source DB: PubMed Journal: Diabetes Spectr ISSN： 1040-9165

77 in total

1. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.

Authors: P Segal; P U Feig; G Schernthaner; K P Ratzmann; J Rybka; D Petzinna; C Berlin
Journal: Diabetes Care Date: 1997-05 Impact factor: 19.112

2. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Authors: Mary Parks; Curtis Rosebraugh
Journal: N Engl J Med Date: 2010-02-17 Impact factor: 91.245

3. Acute renal failure from contrast medium: beware patients taking metformin...

Authors: John A Sayer
Journal: BMJ Date: 2006-09-23

4. Standards of medical care in diabetes--2014.

Authors:
Journal: Diabetes Care Date: 2014-01 Impact factor: 19.112

5. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

Authors: M Pendergrass; C Fenton; S M Haffner; W Chen
Journal: Diabetes Obes Metab Date: 2012-02-20 Impact factor: 6.577

6. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Authors: John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner
Journal: Lancet Date: 2012-11-07 Impact factor: 79.321

Review 7. Oral antihyperglycemic agents and renal disease: new agents, new concepts.

Authors: Jean-François Yale
Journal: J Am Soc Nephrol Date: 2005-03 Impact factor: 10.121

8. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal: Lancet Date: 2009-06-06 Impact factor: 79.321

Review 9. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.

Authors: J A Balfour; D McTavish
Journal: Drugs Date: 1993-12 Impact factor: 9.546

10. Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006.

Authors: Lael Reinstatler; Yan Ping Qi; Rebecca S Williamson; Joshua V Garn; Godfrey P Oakley
Journal: Diabetes Care Date: 2011-12-16 Impact factor: 19.112

1 in total

1. Hypoglycemic and hypolipidemic activity of aqueous leaf extract of Passiflora suberosa L.

Authors: Hasani Prabodha Sudasinghe; Dinithi C Peiris
Journal: PeerJ Date: 2018-02-20 Impact factor: 2.984

1 in total